Arcturus Therapeutics Holdings Inc. (ARCT) research
Arcturus Therapeutics Holdings Inc.- Sector
- Biotechnology
- Last price
- $16.03
- As of
Arcturus Therapeutics Holdings Inc. (ARCT): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-25.
As of . Source: SEC EDGAR filings for ARCT. Method and limitations.
Share the ARCT intelligence card
See ARCT live in the terminal
Track ARCT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ARCT terminal, freeActive signals for ARCT
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +263% to ARCT (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 88% of ARCT (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 52% of ARCT (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +56% to ARCT (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +263% to ARCT (2026Q2)
FREE, NO ACCOUNT
Every signal on ARCT, as it fires
You are seeing 5 of 20 signals recorded on ARCT since 2026-06-10.
The five above all landed on 2026-09-06. The other 15 were recorded on 2 other days. 15 of the 20 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARCT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 03969T109 · 2026Q2 | $7.3M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 03969T109 · 2026Q2 | $2.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03969T109 · 2026Q2 | $2.3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 03969T109 · 2026Q2 | $1.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 03969T109 · 2026Q2 | $275K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03969T109 · 2026Q2 | $144K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARCT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ARCT against its peers
ARCT's operating margin of -93.0% ranks in the 79th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ARCT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 82.0M USD | 13.0M USD | 89 | 13 |
| Operating margin | -93.0% | -394.9% | 79 | 11 |
| Net margin | -80.2% | -395.0% | 79 | 11 |
| Return on equity | -30.7% | -78.4% | 88 | 20 |
Peers (23): ARTV, FENC, CCCC, TTRX, ZURA, EDIT, IRD, GALT, CABA, RLMD, PRTA, LRMR, PROK, PRLD, INDP, BNTC, EVMN, BBOT, MYGN, RCKT, DMAC, OBIO, OCGN. Left out: PRTC (period gap), RZLT (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ARCT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ARCT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ARCTand get the insider, 13F, options, and confluence read in one view.